Sarcoma Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Sarcoma Biopsy Market is projected to expand from USD 300.56 Million in 2025 to USD 380.52 Million by 2031, reflecting a CAGR of 4.01%. Sarcoma biopsy serves as a critical diagnostic process involving the collection of tissue from mesenchymal tumors located in soft tissue or bone to ascertain malignancy and identify histological subtypes. The primary catalyst for this market is the increasing prevalence of sarcomas, which creates an urgent need for precise, early-stage diagnosis to enable effective treatment planning. Furthermore, the rising utilization of minimally invasive, image-guided procedures, such as core needle biopsy, facilitates market growth by providing superior diagnostic yields and lower patient morbidity relative to conventional surgical excisions.

However, the market encounters significant obstacles due to tumor heterogeneity, where inadequate sampling can result in non-diagnostic findings or the risk of tumor seeding. Addressing this risk necessitates highly specialized pathological expertise, which is frequently scarce in resource-limited environments. According to the American Cancer Society, an estimated 13,590 new cases of soft tissue sarcomas were anticipated in the United States in 2024. This substantial incidence rate highlights the critical necessity for accurate biopsy modalities while underscoring the pressure placed on healthcare systems to guarantee precise tumor characterization.

Market Drivers

The increasing global incidence of bone and soft tissue sarcomas acts as a primary driver for the Global Sarcoma Biopsy Market, fundamentally necessitating a higher volume of diagnostic procedures. As the burden of these malignancies rises, healthcare systems are forced to expand their biopsy capabilities to ensure timely identification and staging. This growing demand is underscored by recent epidemiological findings; according to a study published in BMC Public Health in April 2025 titled 'Global burden of soft tissue sarcomas,' the number of global cases reached approximately 96,200. This substantial patient population requires a proportional increase in biopsy throughput and has prompted the development of widespread screening protocols, directly boosting the consumption of biopsy devices and supplies in both emerging and developed markets.

concurrently, the integration of artificial intelligence into diagnostic imaging and pathology is transforming the market by addressing key challenges regarding tumor heterogeneity and diagnostic accuracy. AI algorithms are increasingly utilized to support pathologists in subtyping complex sarcomas, thereby lowering the rates of inconclusive biopsies and the necessity for repeat procedures. For example, data presented at the American Association for Cancer Research Annual Meeting in April 2025 revealed a new AI-based model capable of classifying pediatric sarcoma subtypes with precision up to 95.1%. This technological shift is supported by robust financial backing; the National Cancer Institute reported in July 2025 that funding for Sarcoma Specialized Programs of Research Excellence (SPOREs) totaled $2,375,406 for the fiscal year, investments that enhance diagnostic confidence and drive the adoption of premium, AI-compatible digital pathology solutions.

Market Challenges

The growth of the global sarcoma biopsy market is significantly hindered by the complexity of tumor heterogeneity, which complicates the diagnostic workflow. Mesenchymal tumors frequently display diverse cellular structures within a single mass, meaning standard tissue extraction may fail to collect representative malignant cells. This variability poses a distinct risk of obtaining non-diagnostic results, leading to repeat procedures that increase patient burden and healthcare costs. Moreover, the potential for tumor seeding during improper sampling deters the use of needle-based biopsies in non-specialized centers, thereby limiting the accessible market to a select number of high-volume institutions.

This limitation is compounded by a shortage of pathology professionals who possess the niche expertise required to accurately interpret these complex samples. The inherent rarity of the condition contributes directly to this knowledge gap, as general practitioners seldom encounter these distinct malignancies. According to the Sarcoma Foundation of America, sarcomas accounted for approximately 1 percent of all adult cancer diagnoses in 2024. This low incidence rate means few pathologists accumulate sufficient experience to navigate the risks associated with heterogeneity, creating a bottleneck that restricts the widespread utilization of advanced biopsy products in general clinical settings.

Market Trends

The market is being reshaped by the emergence of fusion gene detection assays, which address the molecular complexity inherent in mesenchymal tumors. Because traditional methods often fail to identify all translocation-associated subtypes, laboratories are increasingly incorporating targeted next-generation sequencing panels into their routine workflows. This transition is supported by clinical data demonstrating the superior yield of comprehensive profiling compared to standard techniques. For instance, according to the Journal of Molecular Diagnostics in November 2024, the study 'SARCP, a Clinical Next-Generation Sequencing Assay for the Detection of Gene Fusions in Sarcomas' found that a novel NGS assay detected gene fusions in 36.5% of the 652 analyzed cases, significantly improving diagnostic resolution for patients with ambiguous histological presentations.

In parallel, there is a shift toward liquid biopsy and circulating tumor DNA analysis to overcome the limitations associated with invasive tissue extraction. This trend is driven by the demand for non-invasive modalities capable of monitoring minimal residual disease and capturing tumor heterogeneity that single-site biopsies might miss. The utility of these blood-based assays is becoming increasingly apparent for managing localized disease. As reported in the Journal of Clinical Oncology in May 2024, in the study 'Molecular residual disease detection using bespoke circulating tumor DNA assays in localized soft tissue sarcoma,' baseline blood samples from patients with localized high-risk soft tissue sarcoma showed a ctDNA positivity rate of 79%, highlighting the technology's viability for real-time surveillance.

Key Players Profiled in the Sarcoma Biopsy Market

• Becton, Dickinson, and Company
• Argon Medical Devices
• Cook Group Incorporated
• UROMED
• STERYLAB S.r.l.

Report Scope

In this report, the Global Sarcoma Biopsy Market has been segmented into the following categories:

Sarcoma Biopsy Market, by Product Type:

• Reusable Devices
• Disposable Devices

Sarcoma Biopsy Market, by End User:

• Hospitals
• Ambulatory Surgical Centers
• Diagnostic Centers

Sarcoma Biopsy Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Sarcoma Biopsy Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.